In the treatment of inflammatory bowel disease (IBD), switching from one infliximab biosimilar to another does not significantly alter trough levels and disease activity, regardless of whether switching for the first or second time, as shown in a study. Likewise, there is no substantial difference noted in time to loss of response using clinically relevant definitions.
Major clinical outcomes are comparable between asymptomatic and symptomatic atrial fibrillation (AF) presentations and likewise reduced by oral anticoagulation (OAC) therapy, a study has shown. In addition, opportunistic screening-detected asymptomatic AF has the same prognosis as that at presentation and similarly responds to anticoagulation thromboprophylaxis.
In drug-naïve Chinese patients with type 2 diabetes (T2D), treatment with the first-in-class, glucose sensitizer dorzagliatin led to sustained glycaemic control, according to updated findings from the 52-week phase III SEED* study presented at ADA 2021.
Between the years 2000 and 2019, vaccination programmes all over the world have averted around 50 million deaths, according to a recent study. In the coming decade, vaccines are expected to save 47 million more lives.
Patients with chronic hepatitis B virus (HBV) infection who were treated with tenofovir had a lower risk of developing severe COVID-19 illness than those treated with entecavir, according to a study presented at the EASL International Liver Congress (ILC) 2021.
COVID-19 infection does not appear to adversely affect ovarian reserve, and thus, the chance of success from assisted reproductive treatment likely remains the same as before infection, suggests a small study presented at ESHRE 2021.
Linzagolix treatment continues to reduce menstrual blood loss (MBL) and pain severity, while improving haemoglobin (Hb) level and quality of life (QoL) up to 52 weeks in women with uterine fibroids, according to two phase III randomized clinical trials presented at ESHRE 2021.
Isolation during the COVID-19 pandemic may lead to deterioration in comorbidities and mental health, according to two studies presented at the European Society of Endocrinology virtual conference (e-ECE 2021).
Once-daily iGlarLixi is superior to twice-daily premixed biphasic insulin aspart 30 (BIAsp 30) in glycaemic control and reducing body weight, along with less risk of hypoglycaemia, in patients with suboptimally controlled type 2 diabetes (T2D) despite treatment with basal insulin plus oral antihyperglycaemic drugs (OADs), according to the SoliMix trial presented at ADA 2021.